Literature DB >> 22968463

Hodgkin lymphoma requires stabilized NIK and constitutive RelB expression for survival.

Stella M Ranuncolo1, Stefania Pittaluga, Moses O Evbuomwan, Elaine S Jaffe, Brian A Lewis.   

Abstract

We have analyzed the role of the REL family members in Hodgkin lymphoma (HL). shRNA targeting of each REL member showed that HL was uniquely dependent on relB, in contrast to several other B-cell lymphomas. In addition, relA and c-rel shRNA expression also decreased HL cell viability. In exploring relB activation further, we found stable NF-κB inducing kinase (NIK) protein in several HL cell lines and that NIK shRNA also affected HL cell line viability. More importantly, 49 of 50 HL patient biopsies showed stable NIK protein, indicating that NIK and the noncanonical pathway are very prevalent in HL. Lastly, we have used a NIK inhibitor that reduced HL but not other B-cell lymphoma cell viability. These data show that HL is uniquely dependent on relB and that the noncanonical pathway can be a therapeutic target for HL. Furthermore, these results show that multiple REL family members participate in the maintenance of a HL phenotype.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22968463      PMCID: PMC3488888          DOI: 10.1182/blood-2012-01-405951

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  46 in total

1.  Regulation of NF-kappa B2 p100 processing by its cis-acting domain.

Authors:  Guoliang Qing; Zhaoxia Qu; Gutian Xiao
Journal:  J Biol Chem       Date:  2004-10-14       Impact factor: 5.157

Review 2.  Lymphoid organ development: from ontogeny to neogenesis.

Authors:  Danielle L Drayton; Shan Liao; Rawad H Mounzer; Nancy H Ruddle
Journal:  Nat Immunol       Date:  2006-04       Impact factor: 25.606

3.  A loss-of-function RNA interference screen for molecular targets in cancer.

Authors:  Vu N Ngo; R Eric Davis; Laurence Lamy; Xin Yu; Hong Zhao; Georg Lenz; Lloyd T Lam; Sandeep Dave; Liming Yang; John Powell; Louis M Staudt
Journal:  Nature       Date:  2006-03-29       Impact factor: 49.962

4.  Aberrant NF-kappaB2/p52 expression in Hodgkin/Reed-Sternberg cells and CD30-transformed rat fibroblasts.

Authors:  Mizuho Nonaka; Ryouichi Horie; Kinji Itoh; Toshiki Watanabe; Naoki Yamamoto; Shoji Yamaoka
Journal:  Oncogene       Date:  2005-06-02       Impact factor: 9.867

5.  Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha.

Authors:  E Cabannes; G Khan; F Aillet; R F Jarrett; R T Hay
Journal:  Oncogene       Date:  1999-05-20       Impact factor: 9.867

6.  Genetic lesions of the TRAF3 and MAP3K14 genes in classical Hodgkin lymphoma.

Authors:  Claudia Otto; Maciej Giefing; Anne Massow; Inga Vater; Stefan Gesk; Matthias Schlesner; Julia Richter; Wolfram Klapper; Martin-Leo Hansmann; Reiner Siebert; Ralf Küppers
Journal:  Br J Haematol       Date:  2012-04-03       Impact factor: 6.998

7.  Stabilization of basally translated NF-kappaB-inducing kinase (NIK) protein functions as a molecular switch of processing of NF-kappaB2 p100.

Authors:  Guoliang Qing; Zhaoxia Qu; Gutian Xiao
Journal:  J Biol Chem       Date:  2005-10-13       Impact factor: 5.157

Review 8.  Autophagy and NF-kappaB: fight for fate.

Authors:  Gutian Xiao
Journal:  Cytokine Growth Factor Rev       Date:  2007-05-07       Impact factor: 7.638

9.  Molecular single cell analysis demonstrates the derivation of a peripheral blood-derived cell line (L1236) from the Hodgkin/Reed-Sternberg cells of a Hodgkin's lymphoma patient.

Authors:  H Kanzler; M L Hansmann; U Kapp; J Wolf; V Diehl; K Rajewsky; R Küppers
Journal:  Blood       Date:  1996-04-15       Impact factor: 22.113

10.  Rescue of TRAF3-null mice by p100 NF-kappa B deficiency.

Authors:  Jeannie Q He; Brian Zarnegar; Gagik Oganesyan; Supriya K Saha; Soh Yamazaki; Sean E Doyle; Paul W Dempsey; Genhong Cheng
Journal:  J Exp Med       Date:  2006-10-02       Impact factor: 14.307

View more
  34 in total

1.  RelA and RelB cross-talk and function in Epstein-Barr virus transformed B cells.

Authors:  A Chanut; F Duguet; A Marfak; A David; B Petit; M Parrens; S Durand-Panteix; M Boulin-Deveza; N Gachard; I Youlyouz-Marfak; D Bordessoule; J Feuillard; N Faumont
Journal:  Leukemia       Date:  2013-09-23       Impact factor: 11.528

Review 2.  Update on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms.

Authors:  Akira Satou; N Nora Bennani; Andrew L Feldman
Journal:  Expert Rev Hematol       Date:  2019-07-31       Impact factor: 2.929

Review 3.  Unexpected functions of nuclear factor-κB during germinal center B-cell development: implications for lymphomagenesis.

Authors:  Ulf Klein; Nicole Heise
Journal:  Curr Opin Hematol       Date:  2015-07       Impact factor: 3.284

4.  Alternative and canonical NF-kB pathways DNA-binding hierarchies networks define Hodgkin lymphoma and Non-Hodgkin diffuse large B Cell lymphoma respectively.

Authors:  Angélica María Gamboa-Cedeño; Mariángeles Castillo; Wenming Xiao; Thomas A Waldmann; Stella Maris Ranuncolo
Journal:  J Cancer Res Clin Oncol       Date:  2019-04-02       Impact factor: 4.553

Review 5.  NF-κB pathways in hematological malignancies.

Authors:  Chiara Gasparini; Claudio Celeghini; Lorenzo Monasta; Giorgio Zauli
Journal:  Cell Mol Life Sci       Date:  2014-01-14       Impact factor: 9.261

6.  RelB, together with RelA, sustains cell survival and confers proteasome inhibitor sensitivity of chronic lymphocytic leukemia cells from bone marrow.

Authors:  Jingjing Xu; Peng Zhou; Wenjuan Wang; Aining Sun; Feng Guo
Journal:  J Mol Med (Berl)       Date:  2013-09-17       Impact factor: 4.599

7.  Lymphotoxin-β receptor-NIK signaling induces alternative RELB/NF-κB2 activation to promote metastatic gene expression and cell migration in head and neck cancer.

Authors:  Rita Das; Jamie Coupar; Paul E Clavijo; Anthony Saleh; Tsu-Fan Cheng; Xinping Yang; Jianhong Chen; Carter Van Waes; Zhong Chen
Journal:  Mol Carcinog       Date:  2018-11-28       Impact factor: 4.784

8.  Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma.

Authors:  Rami Rahal; Mareike Frick; Rodrigo Romero; Joshua M Korn; Robert Kridel; Fong Chun Chan; Barbara Meissner; Hyo-eun Bhang; Dave Ruddy; Audrey Kauffmann; Ali Farsidjani; Adnan Derti; Daniel Rakiec; Tara Naylor; Estelle Pfister; Steve Kovats; Sunkyu Kim; Kerstin Dietze; Bernd Dörken; Christian Steidl; Alexandar Tzankov; Michael Hummel; John Monahan; Michael P Morrissey; Christine Fritsch; William R Sellers; Vesselina G Cooke; Randy D Gascoyne; Georg Lenz; Frank Stegmeier
Journal:  Nat Med       Date:  2013-12-22       Impact factor: 53.440

9.  Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth.

Authors:  Subrahmanya D Vallabhapurapu; Sunil K Noothi; Derek A Pullum; Charles H Lawrie; Rachel Pallapati; Veena Potluri; Christian Kuntzen; Sohaib Khan; David R Plas; Robert Z Orlowski; Marta Chesi; W Michael Kuehl; P Leif Bergsagel; Michael Karin; Sivakumar Vallabhapurapu
Journal:  Nat Commun       Date:  2015-10-12       Impact factor: 14.919

10.  The aryl hydrocarbon receptor repressor - More than a simple feedback inhibitor of AhR signaling: Clues for its role in inflammation and cancer.

Authors:  Christoph F A Vogel; Thomas Haarmann-Stemmann
Journal:  Curr Opin Toxicol       Date:  2017-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.